News

Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that from October 1, 2017, LTL Pharma will succeed the marketing approval in Japan from Astellas, for “Nivadil® tablets 2mg, 4mg” (hypertension treat...

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced the status of acquisition of its own shares as stated below. The acquisition was implemented pursuant to Article 156 which is applicable in accordance with Art...

Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of fidaxomicin (generic name) for the treatment of infectious enteritis (including pseudomembranous colitis1 ) (susceptible strains: fidaxomicin susceptible Clostridium difficile2 ). Fidaxomicin is an oral macrocycli...

Sales (-4.5%), core operating profit (-30.7%) and core profit (-22.7%) for the period decreased due to the impacts such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017. Sales of XTANDI® (enzalutamide) for the treatment of prostate cancer grew. Sales of overactive bladder (“OAB”) treatments Betanis® / Myrbetriq...

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, July 28, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka ) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Ar...